The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

LEBANON, Ind. (WFFT) — Eli Lilly and Company announced another $4.5 billion investment in Lebanon’s LEAP Research and ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The major averages ended Thursday on a down note as oil prices spiked. Here's what CNBC is watching going into Friday.

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Overseas stock markets Thursday settled mixed. The Euro Stoxx 50 fell to a 1-week low and closed down by -0.85%. China's Shanghai Composite is closed for the week-long National Day holiday. Japan's ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

Stocks were lower Thursday as traders weighed a greater-than-expected increase in weekly jobless claims and awaited the U.S.

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...